Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Sells $16,323.45 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 715 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total value of $16,323.45. Following the sale, the chief operating officer now owns 342,764 shares of the company’s stock, valued at approximately $7,825,302.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Fulgent Genetics Stock Performance

NASDAQ FLGT opened at $22.56 on Friday. Fulgent Genetics, Inc. has a one year low of $18.91 and a one year high of $33.97. The company’s 50 day moving average price is $22.32 and its 200 day moving average price is $21.97.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, August 2nd. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The business had revenue of $71.03 million for the quarter, compared to the consensus estimate of $69.07 million. During the same quarter last year, the firm posted ($0.33) EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities analysts anticipate that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Asset Dedication LLC purchased a new stake in shares of Fulgent Genetics during the 2nd quarter valued at about $33,000. nVerses Capital LLC purchased a new position in shares of Fulgent Genetics in the second quarter valued at $43,000. Signaturefd LLC grew its holdings in Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after purchasing an additional 1,132 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Fulgent Genetics during the 2nd quarter worth $63,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in Fulgent Genetics in the 1st quarter worth $178,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.